BioAtla (BCAB) Cash from Investing Activities (2020 - 2023)
BioAtla (BCAB) posted quarterly Cash from Investing Activities of -$8000.0 for Q4 2023, up 74.19% year-over-year from -$4592.6 in Q4 2022, and up 68.0% quarter-over-quarter from -$25000.0 in Q3 2023.
BioAtla (BCAB) Cash from Investing Activities (2020 - 2023) Analysis & Trends
BioAtla's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$8000.0 for Q4 2023.
- In Q4 2023, Cash from Investing Activities rose 74.19% year-over-year to -$8000.0; the TTM figure through Sep 2024 stood at -$8000.0 (up 93.39% YoY), while the FY2023 annual figure was -$98000.0, up 63.02% from the prior year.
- Cash from Investing Activities for Q4 2023 stood at -$8000.0, up from -$25000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$8000.0 in Q4 2023, with the low at -$501000.0 in Q1 2021.
- The 4-year median for Cash from Investing Activities is -$62000.0 (2020), against an average of -$117312.5.
- The sharpest annual moves came in 2021 and 2022: Cash from Investing Activities tumbled 2405.0% in 2021, then jumped 98.0% in 2022.
- BioAtla's Cash from Investing Activities stood at -$395000.0 in 2020, then soared by 77.47% to -$89000.0 in 2021, then jumped by 65.17% to -$31000.0 in 2022, then jumped by 74.19% to -$8000.0 in 2023.
- Business Quant data shows BCAB's Cash from Investing Activities at -$8000.0 in Q4 2023, -$25000.0 in Q3 2023, and -$15000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -8,000.00 |
| Dec 31, 2023 | -8,000.00 |
| Sep 30, 2023 | -25,000.00 |
| Sep 30, 2023 | -25,000.00 |
| Jun 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -15,000.00 |
| Mar 31, 2023 | -50,000.00 |
| Mar 31, 2023 | -50,000.00 |
| Dec 31, 2022 | -31,000.00 |
| Dec 31, 2022 | -31,000.00 |
| Sep 30, 2022 | -58,000.00 |
| Sep 30, 2022 | -58,000.00 |
| Jun 30, 2022 | -166,000.00 |
| Jun 30, 2022 | -166,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Dec 31, 2021 | -89,000.00 |
| Dec 31, 2021 | -89,000.00 |
| Sep 30, 2021 | -99,000.00 |
| Sep 30, 2021 | -99,000.00 |